Radnostix Inc

Radnostix, Inc. (OTCQB: INIS), formerly known as International Isotopes Inc. before its corporate name change, is an Idaho Falls, Idaho-based company founded in 1995 that manufactures and distributes a comprehensive portfolio of radioisotope-focused products for the nuclear medicine, life sciences, and industrial sectors in the United States and internationally. The company operates through five distinct business segments: Theranostics Products, Cobalt Products, Nuclear Medicine Standards, Medical Devices, and Fluorine Products. The Theranostics Products segment participates in the rapidly growing field of theranostics — the integrated use of radioactive compounds for simultaneous disease diagnosis and targeted therapy — a medical paradigm that has seen significant clinical advancement with FDA-approved radioligand therapies for certain cancers. The Cobalt Products segment manufactures cobalt-60 sources used in radiation therapy equipment, industrial radiography, and sterilization applications.<br><br>The Nuclear Medicine Standards segment represents a historically stable core business, producing calibration and reference standards essential for the quality assurance programs of nuclear medicine departments at hospitals and imaging centers — the instruments used to deliver radiopharmaceuticals to patients must be regularly calibrated against certified reference standards to ensure accurate dosing. The company also manufactures sodium iodide I-131 drug product, a radioactive thyroid therapy and thyroid cancer treatment agent that has been a clinical standard of care for thyroid conditions for decades. The Fluorine Products segment addresses the specialized market for fluorine-based radiochemicals used in clinical research and molecular imaging applications, including fluorine-18 labeled compounds used in PET scanning. Radnostix recently completed construction and received an initial NRC license amendment for a dedicated Calibration & Reference Products manufacturing facility, positioning the company for significant production capacity expansion.<br><br>Radnostix, Inc. trades on the OTCQB Venture Market under the ticker symbol INIS and files periodic reports with the Securities and Exchange Commission, including annual Form 10-K and quarterly Form 10-Q reports documenting the company's multi-segment financial performance and regulatory compliance activities. As the medical community's use of radioactive materials for diagnostic imaging and cancer treatment continues to grow — driven by advances in targeted radioligand therapy, the expansion of molecular imaging modalities, and the clinical validation of theranostic approaches across multiple oncology indications — Radnostix's manufacturing capabilities in theranostics products, cobalt sources, and nuclear medicine standards position it as a multi-product participant in the nuclear medicine and radiopharmaceutical supply chain.